Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Lantheus (LNTH)

Tipranks - Fri Feb 27, 11:16AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGXResearch Report) and Lantheus (LNTHResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Argenx Se (ARGX)

In a report released today, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Argenx Se, with a price target of $1227.00. The company’s shares closed last Thursday at $772.18.

According to TipRanks.com, CFA is a 5-star analyst with an average return of 33.4% and a 69.8% success rate. CFA covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Dianthus Therapeutics, and Travere Therapeutics. ;'>

Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $1048.14, implying a 30.8% upside from current levels. In a report issued on February 19, Jefferies also maintained a Buy rating on the stock with a $1008.00 price target.

See the top stocks recommended by analysts >>

Lantheus (LNTH)

Lantheus received a Buy rating from William Blair analyst Andy Hsieh today. The company’s shares closed last Thursday at $77.61.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 11.5% and a 47.1% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Aardvark Therapeutics, Inc., and Corbus Pharmaceuticals. ;'>

Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $76.75, representing a 1.4% upside. In a report issued on February 24, Citizens JMP also maintained a Buy rating on the stock with a $78.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.